Physician profile

Anna C Elmers

Physical Medicine & Rehabilitation · Atlanta, GA

NPI 1063696813

$251.17

in general payments reported to CMS, 2019-2025

10 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$27.90

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Rochester Medical Corporation $51.78 2019
Coloplast Corp $37.31 2019-2020
Amgen INC. $28.82 2019
Teva Pharmaceuticals USA, INC. $27.90 2023 Ajovy
Lundbeck LLC $22.95 2019
Shire North American Group INC $19.57 2019
Merck Sharp & Dohme LLC $18.89 2019
Saol Therapeutics INC. $17.89 2019
Melinta Therapeutics, LLC $14.92 2019
C. R. Bard, INC. & Subsidiaries $11.14 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Anna C Elmers

$251.17

in general payments reported 2019-2025

Years
2019-2023
Top company
Rochester Medical Corporation

https://glasscript.com/doctor/48474/anna-c-elmers

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.